Abstract 581: bbT369, a dual-targeted and CBLB gene-edited autologous CART product, demonstrates anti-lymphoma activity in preclinical mouse models von Certo, Michael, Baldeviano, Christopher, Adams, Sharlene, Asimis, Martin, Astrakhan, Alexander, Chavkin, Andy, Cabral, Maria L., Chu, Jimmy, Debrue, Marie, Desai, Devina, Evans, John, Htun, Pinky, Iniguez, Amanda, Jarjour, Jordan, Johnson, Carl, Kantamneni, Harini, Kurtulus, Sema, Magee, Michael, Martin, Unja, McKenney, Seamus, Miller, Sara, Nambiar, Prashant, Nguyen, Vinh Khang, Nnamani, Mauris, Obrigewitch, Jen, Pechilis, Lisa, Perkins, Molly, Petersen, Christopher, Pinger, Jason, Rogers, Cindy, Rouillard, Nick, Sanson, Kendal, Thompson, Emily, Walter, Collin, Yi, Roslyn, Voytek, Sarah, Gregory, Philip

Volltext